OPTN News and Press, OptiNose Inc. From 03/07/24

2024-03-07 09:14:06 ET OptiNose, Inc. (OPTN) Q4 2023 Earnings Conference Call March 07, 2024 08:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Ramy Mahmoud - CEO Conference Call Participants Thomas Flaten - Lake Street ...

2024-03-07 07:12:54 ET More on OptiNose Seeking Alpha’s Quant Rating on OptiNose Historical earnings data for OptiNose Financial information for OptiNose Read the full article on Seeking Alpha For further details see: OptiNose reports mixed...

PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE’s current nasal poly...

Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...

YARDLEY, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter 2023 and corporate updates, befo...

XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized controlled Phase 3 Clinical Trials (ReOpen1 and ReOpen2) FDA Supplemental New Drug Application Filed with Prescription Drug User F...

2023-12-06 12:41:58 ET More on Mid-day movers $ stocks. Altimmune: Don't Buy The GLP-1 Move-Up Altimmune: Pemvidutide Data Reinforces Obesity Drug Outlook Syros Pharmaceuticals, Inc. (SYRS) Q3 2023 Earnings Call Transcript Altimmune weight-loss drug performed...

2023-12-06 10:00:30 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Biocryst Pharm...

2023-12-06 08:38:42 ET More on pre-market losers and stocks. NeuroSense: A Hold Ahead Of Phase 2b ALS Data NeuroSense ALS candidate meets key study goals Janover inks strategic referral partnership with La Rosa Holdings Seeking Alpha’s Quant Rating on ...

2023-12-06 08:22:11 ET More on OptiNose OptiNose, Inc. 2023 Q3 - Results - Earnings Call Presentation OptiNose, Inc. (OPTN) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on OptiNose Historical earnings data for OptiNose Financia...